Century Tx (IPSC): חוב להון עצמי

The price indicator on the GURU.Markets platform chart for Century Therapeutics (IPSC) is 0.18. Century Therapeutics is developing the serial production of donor-cell-based drugs to build industrial capacity. The business is currently focused on scientific research and patents, with no current cash flow. Meanwhile, the expansion of laboratories is leading to a proportional increase in costs for sterile zones, which temporarily limits the efficiency of the operating leverage.

The development of allogeneic iPSC therapies and the receipt of partnership payments require significant capital, making the analysis of the debt-to-equity ratio critical for assessing the financial stability of Century Therapeutics (IPSC). This indicator relates total liabilities to net assets, determining the business's degree of dependence on borrowed funds: the lower the value, the lower the risk of default and the higher the company's autonomy.